Roth Capital Upgrades Peregrine Pharmaceuticals (PPHM) to Buy
Tweet
Share
E-mailGet Alerts PPHM Hot Sheet
Price: $0.61 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 8
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 8
Join SI Premium – FREE
Roth Capital upgraded Peregrine Pharmaceuticals (NASDAQ: PPHM) from Neutral to Buy with a price target of $2.70 (from $1.25).
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Shares of Peregrine Pharmaceuticals closed at $1.35 yesterday.
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Shares of Peregrine Pharmaceuticals closed at $1.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Crown Castle (CCI) to Overweight
- KeyBanc Upgrades EPR Properties (EPR) to Overweight
- Royal Bank of Canada (RY:CN) (RY) PT Raised to Cdn$311 at CIBC
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
